Abstract
Small cell lung cancer (SCLC) is a deadly cancer with a 5-year survival of less than 7%. Immune checkpoint blockade was recently approved but survival benefits are limited. nemvaleukin alfa (‘nemvaleukin’; formerly ALKS 4230), a novel engineered IL-2 fusion protein currently under phase I/II study, is designed to selectively expand tumor-killing CD8+ and NK cells. Here, utilizing a novel SCLC murine model, we investigated the effects of RDB 1462, the murine ortholog of nemvaleukin, on tumor growth and immune cell profiles.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
